Kornimate/medical-research-clean huggingface dataset:
the tracking molecular evolution for nsclc (t-menc) study

Conditions: Lung Neoplasms; Lung Cancer; Nonsmall Cell Lung Cancer; Adenocarcinoma of Lung

Summary: tumor genomic clonal evolution assessed with liquid biopsy of stage ib,ii and iiia non-small cell lung cancer patients after getting radical resection. plasma circulating tumor dna (ctdna) analysis detects molecule residual disease and predicts recurrence in patients. the concordance of the relative abundance of mutations in plasma ctdna with cancer recurrence.

in the study, 200 of stage ib,ii and iiia non-small cell lung cancer patients obtained radical resection will be recruited. all the patients will receive biopsy genotype assay and ctdna liquid biopsy. the abundance of mutations of ctdna was tracked at 4 time points, including: 1. st: 10 days after patients received radical resection. 2. nd: when patients finished the chemotherapy or target drug delivery two cycles. 3. rd: 10 days after patients finished the chemotherapy or target drug delivery four cycles. 4. th: when tumor recrudescence / 2 years after radical resection. tumor genomic clonal evolution was assessed by analyzing the relative abundance of mutations in plasma circulating tumor dna (ctdna).

Eligibility criteria:
inclusion criteria: 1. provision of informed consent and assigned. 2. newly diagnosed and histological or cytological confirmed stage ib-iiia lung adenocarcinoma or non-smoking squamous cell carcinoma patients according to the ajcc staging system. 3. expected radical resection. 4. patients expected more than 3 months of survival time. 5. willingness to comply with required protocols and give permission to use the data for clinical research and products development. exclusion criteria: 1. patients who want neo-adjuvant therapy. 2. patients with t3-4n1 pancoast tumors (superior sulcal tumors). 3. multi-station n2 non-small cell lung cancer with lymph node metastasis. 4. eastern cooperative oncology group (ecog) performance status \> 2 after postoperative chemotherapy 5. eastern cooperative oncology group (ecog) performance status \> 4 after postoperative targeted therapy. 6. patients must never ever has received for any history of radiotherapy/ chemotherapy/surgery before. 7. patients have other primary cancers. 8. known central nervous system metastasis. 9. patients expected less than 3 months of survival time. 10. other situations mismatch this program.
registry study of proton radiotherapy in lymphoma

Conditions: Mediastinal Lymphoma

Summary: the aim is to record and document a mediastinal pt and the corresponding follow-up data (effectiveness and side effects). general recommendations for planning and feasibility are made within the framework of this study.

improvements in multimodal therapy have resulted in high curation rates in lymphoma patients. in addition, these cancer entities (hodgkin lymphoma and non-hodgkin lymphoma) often affect very young patients. due to the high healing rates, the long-term effects of therapy are increasingly coming into focus: more than 40% of patients suffer from chronic, therapy-associated secondary diseases 30 years after successful therapy \[1\]. for this reason, an important focus of current research is the reduction of therapy-associated toxicity. a certain trend of dose reduction and reduction of the radiation fields (involved-field, involved-node, involved-site radiation) can already be seen in the research results of the last decades. another interesting approach to protecting adjacent organs is the use of modern radiation techniques such as particle therapy with protons (pt). in the case of radiation in the mediastinal area in particular, the use of pt can greatly reduce the dose in the area of the heart muscle, the lungs or the mammary gland tissue compared to conventional radiation with photons. it is hoped that this will result in a decrease, especially in chronic side effects, in the area of these organs. since this is a group of young patients with intensive pre-treatment with chemotherapeutic agents, a reduction in long-term toxicities is of particular importance. in particular, cardiac and pulmonary long-term side effects as well as a reduction in the secondary malignancy rate play a major role in this collective. the aim of this prospective registry study on proton radiotherapy for mediastinal lymphomas is to record the frequency, feasibility and side effects after pt in this group of patients. these data should then serve as the basis for concrete therapy recommendations and assessment of side effects. close cooperation with the study groups should also enable a comparative analysis of comparable patients who were not treated with protons at a later point in time.

Eligibility criteria:
inclusion criteria: histologically confirmed lymphoma according to who * patient consent * patient age ≥18 years. * presence of the need for mediastinal radiotherapy and the presumed benefit of mediastinal radiotherapy using protons in comparison to photon radiation (e.g. improved heart, lungs, and breast protection compared to photon radiation). * ability of the patient to give consent exclusion criteria: age \<18 years * non-consent of the patient to the disclosure of his data * cancellation of the patient's participation in the study
pro 140 for human immunodeficiency virus infection

Conditions: HIV

Summary: pro 140 2103 is a multicenter, randomized parallel group study, conducted in male and female adult subjects infected with ccr5-tropic hiv-1.

protocol pro 140 2103 is a multicenter, randomized parallel group study, conducted in approximately 40 male and female adult subjects (n=10/treatment group) infected with ccr5-tropic hiv-1. subjects will be randomized into one of four treatment groups. blood samples for drug concentrations, pd variables, and efficacy variables will be obtained over a 59-day period following initiation of dosing. safety will be monitored throughout the course of the study.

Eligibility criteria:
inclusion criteria: 1. males and females, age ≥18 years 2. has not taken any antiretroviral therapy (art) within 12 weeks of the early screening visit 3. screening plasma hiv-1 rna ≥ 5,000 copies/ml 4. cd4+ lymphocyte cell count ≥500 cells/mm3 and no documented count less than or equal to 250 cells/mm3 5. exclusive ccr5-tropic virus as determined by as determined by the enhanced sensitivity trofile™ hiv tropism assay 6. clinically normal resting 12-lead ecg at screening visit 7. women of reproductive potential must have a negative serum pregnancy test at late screening visit. within hours prior to receiving the first dose of study drug, women of reproductive potential must have a negative urine pregnancy test. male and female subjects must agree not to participate in a conception process and agree to use one barrier method of contraception plus one other highly reliable contraceptive method from the early screening visit through three weeks after the last administered subcutaneous dose of pro 140. exclusion criteria: 1. cxcr4-tropic virus, dual/mixed tropic (r5x4) virus as determined by the enhanced sensitivity trofile™ hiv tropism assay 2. females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study 3. diagnosis of acute viral hepatitis (defined as any active infection with hepatitis a or a new diagnosis of hepatitis b or c within 24 weeks of dosing) 4. chronic hepatitis 5. prior use of any entry, attachment, ccr5 coreceptor, or fusion inhibitor, including pro 140, experimental or approved 6. any immunization or vaccination (including influenza vaccine) within 30 days prior to administration of study drug.
etrasimod versus placebo for the treatment of moderately to severely active ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis.


Eligibility criteria:
inclusion criteria: 1. diagnosed with ulcerative colitis (uc) ≥ 3 months prior to screening 2. active uc confirmed by endoscopy exclusion criteria: 1. severe extensive colitis 2. diagnosis of crohn's disease (cd) or indeterminate colitis or the presence or history of a fistula consistent with cd 3. diagnosis of microscopic colitis, ischemic colitis, or infectious colitis

Keywords: ulcerative colitis etrasimod apd334
acute effects of glucose dependent insulinotropic polypeptide (gip) on subcutaneous adipose tissue

Conditions: Metabolic Syndrome; Obesity; Insulin Sensitivity

Summary: this clinical, randomized, cross-over study in obese healthy subjects aimed to analyse the acute effects of the incretin hormon glucose dependent insulinotropic polypeptide (gip) on metabolic parameters and gene expression in subcutaneous adipose tissue.


Eligibility criteria:
inclusion criteria: * bmi \> 28 * healthy subjects * normal glucose tolerance exclusion criteria: * diabetes,ifg, igt * chronical-inflammatory diseases * hb \< 12g/dl * elevation in liver enzymes or creatinin concentrations * great weight changes within last 12 months * any cancer diagnosis in last 10 years

Keywords: euglycemic-hyperinsulinemic clamp fat biopsies microarray analysis quantitative real time pcr overnutrition low grade-inflammation
dexmedetomidine cardiovascular safety in pediatric burn patients

Conditions: Burns; Sedation

Summary: dexmedetomidine is a sedative drug approved for adult patients, intubated, in intensive care units. we are studying whether this drug is cardiovascularly safe in pediatric patients who have recently been burned.

this is an ascending dose study evaluating the cardiovascular safety of dexmedetomidine bolus/infusions in acutely burned pediatric patients. the study entails a bolus of dexmedetomidine, followed by 2 hours of increasing infusion doses. cardiovascular parameters including ekg, heart rate, oxygen saturation, blood pressure, are recorded.

Eligibility criteria:
inclusion criteria: * pediatric patient * \>25% total body surface area (tbsa) burn and \< 90% tbsa * opioid requirements \> 0.1 mg/kg/hour of morphine (or equivalent) * midazolam requirement \> 0.1 mg/kg/hour * treatment team determined that patient should be started on dexmedetomidine exclusion criteria: * hemodynamically unstable patients (epinephrine \> 1.0 ug/kg/min, levophed \> 0.75 ug/kg/min, dopamine \> 10 ug/kg/min) * pregnant patients * patients with history of heart block * patients with congenital heart disease * patients with significant hepatic dysfunction * patients with urine output \< 0.5 ml/kg/hour \[averaged\] over past 24 hours

Keywords: pediatric burn sedation
hand-foot exercises on peripheral neuropathy

Conditions: Breast Cancer; Neuropathy

Summary: this study will be conducted to compare the effects of hand and foot exercises on peripheral neuropathy and quality of life in breast cancer patients taking taxanes

i̇ntroduction: new evaluation and care strategies for symptom control are gaining importance due to the increasing prevalence of cancer, expansion of chemotherapy indications, and the development of new chemotherapeutic agents with side effects such as peripheral neuropathy and pain. in the literature review, although there are studies evaluating the effects of neuropathic pain, neuropathy on quality of life and daily living activities, it was determined that there are a very limited number of studies on reducing chemotherapy-induced neuropathy. simple, at-home exercises to prevent neuropathy can be done daily in a short period of time and do not require special equipment. these exercises may serve as an alternative therapy to improve quality of life by reducing pain in people with neuropathy. purpose: this study will be conducted to compare the effects of hand and foot exercises on peripheral neuropathy and quality of life in breast cancer patients taking taxanes. method: this study will be conducted using a randomized controlled research design. the research sample will consist of 84 women with breast cancer receiving chemotherapy in the chemotherapy unit of a training and research hospital. research data will be collected using the introductory information form, visual analog questionnaire (vas), national cancer institute common terminology criteria for adverse events version 5.0 (nci-ctcae v5.0) -peripheral neuropathy, eortc qlq-cipn 20. the exercise program will start the week the first neuropathy symptom appears and continue for 8 weeks. data will be collected in two time periods: the week of starting exercise (t1) and the 8th week after exercise (t2). conclusion: it is thought that home-based, simple exercise practices will reduce neuropathy symptoms and improve the quality of life in women with breast cancer receiving neurotoxic chemotherapy.

Eligibility criteria:
inclusion criteria: * the age of 18-80 years * clinical diagnosis of breast cancer * must be able to read and speak turkish * must be the first time the taxane group receives chemotherapy * must be have at least grade 1 neuropathy according to ctcae * must agree to participate in the study exclusion criteria: * presence of peripheral neuropathy conditions not caused by chemotherapy \[tumor compression, nutritional disorders, infections, neurological diseases such as stroke, diabetes, etc.\] * skin infection, scar tissue, inflammation, or cuts on the hands or feet * neuropsychiatric disease
accurate classification system for patients with covid-19 pneumonitis

Conditions: Pneumonitis

Summary: the covid-19 has a clustering morbidity trend and older people with chronic diseases are more likely to die, such as chronic renal insufficiency and chronic cardiovascular disease. we set up a covid-19 pneumonia grading scale. the covid-19 score system was validated to predict the clinical outcome of a patient.

1. first we collect the medical records, according to the time sequence, the patients were divided into two groups, one is the model group, and the other is the validate group. 2. responsible for the risk factor of regression equation according to the model. the patients were divided into three groups according to their total score of risk responsibility. 3. compared with sepsis and curb-65 grading system with the grading system we established.

Eligibility criteria:
inclusion criteria: * patients with novel coronavirus pneumonia should be examined and diagnosed by ct and swab test of viral nucleic acid. exclusion criteria: * patients who should have died during the course of the disease, but the cause of death was unrelated to viral pneumonia. * suspected patient review refers to the negative nucleic acid test.
tele-electrocardiography in emergency cardiac care

Conditions: Myocardial Infarction; Chest Pain

Summary: the purpose of this study is to see whether individuals who access the "911" emergency medical system with a heart attack or severe chest pain will receive more timely hospital treatment and better outcomes if hospital clinicians are provided with earlier and more complete electrocardiography (ecg) information.

this is a phase iii study. patients will be randomized (like tossing a coin) to 1 of 2 groups: group 1: patients will have pre-hospital ecg intervention. group 2: patients will have routine emergency heart care. information will be collected about time symptoms started, clinical management, and other measures. all patients will be contacted by telephone 12 months later and interviewed as to whether they experienced any cardiac symptoms.

Eligibility criteria:
inclusion criteria: * all individuals in santa cruz county in california who call 911 with symptoms of acute coronary syndrome (chest pain, shortness of breath, anginal equivalent). exclusion criteria: * those who don't meet the above inclusion criteria.

Keywords: telemedicine emergency care cardiac
recolonization following preoperative disinfection plastic adhesive drapes

Conditions: Surgical Wound Infection

Summary: the purpose of this study is to measure the time to recolonization intraoperatively after preoperative disinfection with chlorhexidine solution in ethanol and to determine evidence of differential bacterial growth with or without plastic adhesive drape on the chest as well as with or without microbial sealant on the leg.

the purpose of this study is to measure the time to recolonization intraoperative after preoperative disinfection with chlorhexidine solution in ethanol and to determine evidence of differential bacterial growth with or without plastic adhesive drape as well as with or without microbial sealant on the leg. a rct study of 140 patients undergoing coronary artery bypass grafting (cabg) and/or aortic valve replacement (avr) are included. the investigators test the hypothesis that patients randomized to no plastic adhesive drape intraoperatively will have a reduced recolonisation compared to patients with plastic adhesive drape.

Eligibility criteria:
inclusion criteria: elective cabg and/or avr exclusion criteria: suffer from any recent infection two weeks prior to the start of the trial

Keywords: recolonization plastic adhesive drape microbial sealant ssi bacterial growth
milrinone in addition to hyperdynamic therapy in the treatment of vasospasm following aneurysmal subarachnoid hemorrhage

Conditions: Cerebral Vasospasm

Summary: the purpose of this study is to evaluate the usefulness of adding milrinone to the current standard treatment for cerebral vasospasm.

the goal of this study is to assess the efficacy of milrinone as an agent to treat cerebral vasospasm by adding it to standard therapy. this will take the form of a randomized, controlled trial in which patients will receive either standard hyperdynamic therapy or hyperdynamic therapy + milrinone. the hypothesis of this study is that good outcomes will be 25% more common in the experimental (milrinone) group than the control (standard therapy) group.

Eligibility criteria:
inclusion criteria: * subjects ≥ 18 years of age * aneurysmal subarachnoid hemorrhage, proven on ct angiogram or digital subtraction angiography * aneurysm treated, either by endovascular embolization or surgical clip ligation * evidence of increased velocities on transcranial dopplers (tcds) and/or radiographic evidence of vasospasm as seen on angiogram * cerebral vasospasm as demonstrated by patient's clinical exam (new focal deficit or change in mental status not attributable to any other cause) exclusion criteria: * recurrent subarachnoid hemorrhage * untreated ruptured aneurysm, for any reason * patients who die prior to treatment for aneurysm * patients who are not able to complete at least 6 months of follow-up * patients who are admitted already in vasospasm (i.e. a delayed admission) * creatinine clearance less than 20 ml/min * women with a positive pregnancy test or who are lactating * other comorbidity which may adversely affect patient outcome, at the discretion of the principal investigator

Keywords: subarachnoid hemorrhage cerebral vasospasm milrinone hyperdynamic therapy
physiotherapy program effect on musculoskeletal dysfunctions in young football players

Conditions: Flatfoot, Flexible; Pes Valgus; Pes Varus; Balance; Distorted; Diastasis; Weak; Muscle

Summary: the goal of this clinical study is to test the proposed physiotherapy exercise program in young football players. the main question it aims to answer is: - does the proposed physiotherapy program work well in improving young football players movement apparatus functions? participants will be asked to fill out questionaires about their musculoskeletal health, physical activity and foot wear and follow the 8 weeks of the group exercise program of 16 sessions in total (2 sessions per week, 30 minutes each session). researcher will compare exercising participants with no exercising participants of the same age and football category to see if the exercise program works well in young football players.

the clinical trial aims to evaluate the short and long term effect of proposed neurophysiology-based physiotherapy program (npp) on selected functional variables of the lower body in young football players, using clinical and laboratory diagnostic methods. participants will be randomly assigned into one of the two groups: experimental (following 8 weeks of the intervention program) and control group (not changing the movement habits). proposed npp combines techniques and concepts based on neurophysiology principles and developmental kinesiology: sensorimotor stimulation and foot exercises, balance training, trunk stabilisation exercise in developmental kinesiology positions. participants will exercise in small group twice a week in total of 16 sessions, 30 minutes each of session, under the guidance of an experienced physiotherapist. npp is designed as a step by step progressive exercise program with focus on quality of neuromuscular control. whole program is implemented into the standard football training process. data will be obtained pre- (at baseline) and post-intervention (in 2 months and in 5 months) and compared to control group.

Eligibility criteria:
inclusion criteria: * participants playing football at sub- to elite level exclusion criteria: * acute infectious disease or fever * any serious cardiological, neurological, or orthopedic diseases * acute pain * injury in the last 3 months * currently undergoing any other kind of physiotherapy or treatment * missing two or more sessions of the intervention program

Keywords: dynamic neuromuscular stabilisation pronated foot postural stability neuromuscular control exercise sportive children functional stabilisation foot function soccer